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Quantification of orotic acid (uracil-6-carboxylic acid) in urine is an important tool to diagnose some
inherited diseases, such as urea cycle disorder (OTCD) and hereditary orotic aciduria. New rapid
analytical methods are necessary to provide high-throughput orotic acid analyses. A new analytical
method has been developed for the rapid analysis of orotic acid in urine by liquid chromatography
coupled with ion spray tandem mass spectrometry (LC/MS/MS). After a sample dilution 1:20, the
analysis was performed in the selected reaction monitoring mode in which orotic acid was detected
through the transition m/z 155 to 111. The retention time was 3.9 min in a 4.5-min analysis. Daily
calibration between 0.5–5.0mmol/L of orotic acid, corresponding to 10–100mmol/L in urine before
the 1:20 dilution, offered consistent linearity and reproducibility. Interassay coefficient of variance
(c.v.) was 4.97% at a mean concentration of 10.99mmol/L. The sensitivity and specificity of tandem
mass spectrometry permitted a high volume of analyses of orotic acid. The sample preparation is
simple, inexpensive and not time demanding. Copyright # 2003 John Wiley & Sons, Ltd.
The analysis of orotic acid (OA) is used in clinical chemistry to
diagnose some diseases associated with urea cycle disorders;
ornithine transcarbamylase deficiency (OTCD)1 is the most
common, and also hereditary orotic aciduria.2 The urea cycle
has three roles: it produces urea as the waste product incor-
porating nitrogen not used for biosynthetic purposes, it is
involved in the biochemical reactions that degrade and
synthesise arginine de novo, and it plays a fundamental role
in pH homeostasis.3
Ornithine transcarbamylase, a mitochondrial matrix
enzyme, catalyses the synthesis of citrulline from carbamyl
phosphate and ornithine. OTCD male patients show classical
clinical symptoms such as vomiting, lethargy, and confusion;
clinical laboratory indications are high values of glutamine
and ammonia, low citrulline, and high urinary excretion of
orotic acid. Also, female manifesting carriers generally have
higher than normal values of urinary orotic acid excretion
due to X-inactivation.
Hereditary orotic aciduria is a pyrimidine synthesis defect
caused by uridine-50-monophosphate (UMP) synthase defi-
ciency.4 This multienzyme catalyses the synthesis of UMP
starting from orotic acid via orotidine-50-monophosphate.
Some characteristic clinical features are anaemia, hematuria,
pallor, diarrhoea, retarded and poor development, while
laboratory indications include very high urinary orotic acid
excretion.
Therefore, determination of orotic acid levels in urine
is becoming an assay routinely performed in clinical
analysis.5–13 To date, orotic acid has been determined mostly
by liquid chromatography (HPLC) with UV detection at
275 nm.14 This approach is quite cumbersome in the
subsequent integration and interpretation process. Signals
from a ‘normal’ specimen are quite difficult to quantify since
the LC-UV peaks are very close to the baseline (lack of
adequate sensitivity) and are sometimes not sufficiently
resolved from other endogenous components owing to the
nonspecific wavelength chosen for detection. In addition the
chromatographic run is time demanding.
In this paper we evaluate the possibility to take advantage
of tandem mass spectrometry15 (MS/MS) as the basis for a
rapid method for determination of OA in urine with very
simple preparation, which could be a candidate for high-
throughput routine analyses. The main criteria in developing
a robust high-throughput analytical method center around
minimal sample preparation, no derivatization, high sensi-
tivity and specificity, high throughput capability, and
minimal instrument maintenance. It was hoped that such a
method would provide a suitable tool for a large-scale
investigation.
EXPERIMENTAL
Materials
An orotic acid standard was purchased from Sigma-Aldrich
(Steinheim, Germany), and a stock solution was made in
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water (corresponding to 1 mg/mL OA). Successive dilutions
were made using a 50% aqueous solution of acetonitrile con-
taining 5 mmol/L ammonium acetate. All chemicals and sol-
vents were of the highest purity available from commercial
sources and were used without further purification.
Sample preparation
Urine samples were prepared by dilution (1 vol. urineþ
19 vol. water containing 0.1% formic acid). For the purposes
of this study, urine samples with different creatinine concen-
trations were spiked with known amounts of orotic acid. 2 mL
of the diluted samples were injected for the LC/MS/MS
experiments.
Methods
An Applied Biosystems-Sciex (Toronto, Canada) API 2000
bench-top triple-quadrupole mass spectrometer, equipped
with a TurboIonSpray source, was employed for this study.
The TurboIonSpray source was operated in negative ion
mode with a needle potential of 4800 V and with a ‘turbo’
gas flow of 10 L/min of air heated at 3008C (nominal heating-
gun temperature). Mass calibration and resolution adjust-
ments on the resolving quadrupoles were performed auto-
matically by using a 104 mol/L PPG solution introduced
via the built-in infusion pump. The peak width was set on
both resolving quadrupoles at 0.7 Th (measured at half
height) for all MS and MS/MS experiments.
Collision-activated dissociation (CAD) MS/MS was per-
formed in the LINAC Q2 collision cell, operating with
10 mTorr pressure of nitrogen as collision gas. The decluster-
ing potential (DP) and collision energy (CE) were automati-
cally optimized for orotic acid using the instrument software.
The resulting DP was10 V, and optimal CE was found to be
12 eV (laboratory frame).
MS and MS/MS spectra were collected in continuous flow
mode by connecting the infusion pump directly to the
TurboIonSpray source. A standard solution of 10 ng/mL of
OA in an aqueous solution of 50% acetonitrile containing
5 mmol/L ammonium acetate was infused at 10mL/min. The
quantitation experiments were performed using a series 1100
Agilent Technologies (Waldbronn, Germany) CapPump
coupled to an Agilent Micro ALS autosampler, both fully
controlled from the API 2000 datasystem. Liquid chromato-
graphy was performed using a Phenomenex Luna C18 5mm,
3 150 mm HPLC column (Chemtek-Analitica, Anzola
Emilia, Italy). Column flow rate was 0.45 mL/min using an
aqueous solution of 60% acetonitrile containing 0.1% formic
acid. The eluent from the column was directed to the
TurboIonSpray probe with a split ratio of 1:5.
The acquired data were processed using the Analyst 1.1
proprietary software including the ‘Explore’ option (for
chromatographic and spectral interpretation) and the ‘Quan-
titate’ option (for quantitative information generation).
RESULTS AND DISCUSSION
Figure 1 shows the structure of orotic acid. Figure 2 shows the
mass spectrum collected via infusion through the TurboIon-
Spray probe at 10 mL/min of a solution of 10 ng/mL of orotic
acid. The [M–H] ion is clearly observed atm/z 155.1. Figure 3
shows the MS/MS spectrum obtained by fragmenting the
[M–H] precursor ion of OA using the conditions described
above. From these experiments, the MS/MS transition cho-
sen for the quantitative experiments (selected reaction mon-
itoring, SRM) is m/z 155.1! 111.1. Figure 4 displays a typical
calibration curve obtained in the concentration range 0.5–
5.0 mmol/L (10–100 mmol/L before the 1:20 dilution).
Figure 5 shows the SRM chromatograms obtained for a stan-
dard solution (1.0mmol/L, left) and a urine sample (right)
containing 1.6 mmol/L diluted 20-fold. Chromatographic
conditions were chosen in order to minimise the run time
(less than 4.5 min) since the outstanding specificity is pro-
vided by the MS/MS detection. Comparison of the two panes
of Fig. 5 indicates that the bulk of the matrix does not lead to
any extra chromatographic peaks by this method.
The sample dilution ratio (20:1) and injection volume (2 mL)
were selected in order to not overload the chromatographic
column even after a considerable number of sample injec-
tions (the equivalent of 0.1 mL of original urine is introduced
through each single injection); the injection sample volume
was selected after several trials. The dilution was made with
water and no organic solvent, resulting in a solvent with
weaker elution capabilities than the LC eluent used for
reversed-phase LC; this was intended to pack the injected
sample plug at the front end of the column. The outcome is
that the column shows robust performance as long as only
0.1 mL of the original urine is loaded (2 mL of 20diluted
sample), whatever the salt concentration in the specimen
(expressed by the creatinine concentration in the present
application).
Concerning calibration, it was considered that external
calibration with aqueous standards was sufficient for the
present purpose. To test this, a range of urine samples with
very different densities and creatinine concentrations were
spiked with 10mmol/L of OA. Samples were processed and
quantitated by comparison with aqueous standards as
described in the Experimental section (results are reported
without normalisation for the creatinine content). As an
example, Table 1 reports the data obtained for three samples,
with low (0.58 mmol/L), medium (2.3 mmol/L) and high
(3.74 mmol/L) creatinine concentrations.
Including all the other samples examined, discrepancies
between spiked values and measured values using external
calibration with aqueous standards were within 6%. These
data lead to the conclusion that a simple external calibration
with aqueous standard should be viable in these experi-
mental conditions, for present purposes.
In order to assess the robustness of the method, several
urine samples with different creatinine contents were
processed several times, resulting an intra-day reproduci-
Figure 1. Structure of uracil-6-carboxylic acid (orotic acid).
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Figure 2. Mass spectrum in negative-ion mode recorded by infusing a solution of 10 ng/mL of orotic acid.
Figure 3. MS/MS spectrum obtained by fragmenting the [M–H] precursor ion (m/z 155.1) of OA in
negative-ion mode with a collision energy of 12 eV.
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bility below 6.4% for values above 5mmol/L (see Table 2). In
an inter-day reproducibility test, reproducibility values
better than 5% were obtained (see Table 3).
With the proposed experimental parameters, the estimated
limits of detection (signal-to-noise (S/N)¼ 3) in urine were
0.15 mmol/L. With the same experimental parameters, the
Figure 4. Typical calibration curve obtained in the concen-
tration range 0.5–5.0mmol/L of orotic acid, corresponding to
10–100mmol/L in urine before the 1:20 dilution.
Figure 5. SRM chromatograms obtained for a standard solution (1.0 mmol/L, left) and a urine sample
(right) containing 1.6mmol/L OA, 20 times diluted.
Table 1. Determination of OA in urinewith different creatinine
concentrations, against aqueous calibration standards without
internal calibration
OA concentration
mmol/L
Creatinine
concentration
mmol/L
Determina-
tion against
aq. standard
(no IS) mmol/
L (%)
Ratio Read/
Calculated
1.02 0.58 1.00 98.0
11.02 0.58 10.44 94.7
0.97 2.3 0.97 100.0
10.97 2.3 10.3 93.9
1.36 3.74 1.4 102.9
11.36 3.74 11.52 101.4
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limits of quantitation in urine (S/N¼ 10) were 0.383 mmol/L.
No deterioration in column efficiency was observed after
analysis of 200 urine samples.
CONCLUSIONS
The proposed method is characterised by a fast and very sim-
ple sample preparation. Calibration is made externally with
aqueous standards with no need for expensive isotopically
labeled standards. Instrumental analysis time is less than
4.5 min. Fast chromatography, combined with the specificity
provided by tandem mass spectrometric detection, allows for
a fast, robust and specific procedure for OA determination.
Several factors have made it possible to develop this simple
application. These include the good MS/MS sensitivity in
negative-ion mode even with the presence of formic acid
(0.1%) in the chromatographic eluent, the MS/MS specificity
guaranteed even at such low m/z values by the resolution set
for both quadrupoles (peak widths 0.7 Th, FWHM), and the
robustness of the TurboIonSpray interface, which makes
possible the injection of crude samples after a simple dilution,
even without the need for an internal standard. The latter
aspect is possible provided that the chromatographic reten-
tion factor (k-factor) is large enough relative to the column
void volume.
The detection limit of 0.15 mmol/L of OA in urine should
not be regarded as the ultimate figure since an increase of
sensitivity could be expected by downsizing the LC column
diameter. However, the value achieved here seems to fulfill
the sensitivity requirements of the present application, and it
has been decided to stay with the 3.0-mm column since it is
more robust for several hundreds of injections. Switching to a
smaller column, e.g., 1 mm i.d., should increase the sensitiv-
ity by a factor of about one order of magnitude.
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